Cellectar Biosciences Inc (CLRB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.37+0.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CLRB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CLRB — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026, we issued a press release announcing our financial results for the quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Why it matters: Updates on CLR 125's trial can show progress in treating triple-negative breast cancer.
Supportive ifThere are positive safety and efficacy updates from the CLR 125 Phase 1b trial.
Worry ifThere is negative safety or efficacy data from the CLR 125 trial.
Why it matters: Raising capital can help the company’s finances. Investors will look at how it affects operations.
Watch forThe company had a successful stock sale. It raised over $3M.
Also watch forCompany does not raise capital or says there will be a big delay.
Why it matters: The FDA submission is key for faster approval. This affects future income and patient access.
Supportive ifThe New Drug Application is submitted in mid-2027 as planned.
Worry ifDelay in the New Drug Application submission beyond mid-2027.
Why it matters: Maintaining cash is critical for funding operations. Low cash could signal financial trouble.
Worry ifThe company has enough cash to fund operations until Q3 2026.
Less concerning ifThe company has less cash than needed to fund operations until Q3 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$197 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $733 loss on $10,000 · 7.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,386 loss on $10,000 · 63.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash balance can indicate if Cellectar can fund its operations and trials. This affects investor confidence.
Supportive ifCash and cash equivalents are over $34 million in the next quarterly update.
Worry ifCash balance drops below $20 million, raising concerns about funding.
Why it matters: This trial shows Cellectar can create new cancer treatments. It shows the company's growth.
Supportive ifEnrollment and dosing of additional patients in the CLR 125 trial is reported by the end of 2026.
Worry ifNo new patient enrollments or dosing updates by the end of 2026.
Why it matters: Good results may help speed up FDA approval. This could make investors more confident.
Supportive ifGood results for Iopofosine I 131 were shown at ASCO for r/r WM patients.
Worry ifBad or unclear results for Iopofosine I 131 were shown at ASCO.
Why it matters: Starting the Phase 3 trial is a key step toward FDA approval. It shows progress in Cellectar's cancer treatment strategy.
Supportive ifThe first patient is dosed in the Phase 3 trial for iopofosine I 131 by early 2027.
Worry ifThe trial does not start as planned, delaying the timeline for FDA submission.
Why it matters: The FDA's decision on the application will be crucial for Cellectar's future. It can affect the company's market position.
Watch forFDA gives quick approval for iopofosine I 131 for r/r WM.
Also watch forFDA denies or delays the request for iopofosine I 131.
Why it matters: Good data could raise confidence in iopofosine I 131. It may affect how investors feel.
Watch forPositive results from the CLOVER WaM study will be shown at the ASCO 2026 Meeting.
Also watch forBad or unclear data will be shown at ASCO 2026.
Why it matters: Cash balance updates will show if the company can pay for operations and trials until 2027.
Watch forCash balance is enough to support operations until Q2 2027.
Also watch forA big drop in cash balance or signs of funding problems are concerning.
Why it matters: Maintaining cash is vital for funding ongoing trials and operations.
Worry ifCash balance remains above $30 million and funds operations into Q2 2027.
Less concerning ifCash balance falls below $20 million or funding issues arise.
Why it matters: Updates on CLR 125's trial can show how well the drug works in a tough cancer type. This could impact investor confidence.
Supportive ifManagement shares good news from the Phase 1b trial of CLR 125 in TNBC.
Worry ifNegative trial results or delays in data updates from the CLR 125 trial.
Why it matters: Cellectar has high operating losses. This may mean bigger money problems.
Worry ifOperating loss in Q2 2026 exceeds $6 million.
Less concerning ifOperating loss in Q2 2026 is less than $5 million.